An update on TroVax® for the treatment of progressive castration-resistant prostate cancer

• Main Authors: Abern M, Kaufman HL, Latchamsetty K
• Format: Article
• Language: English
• Published: Dove Medical Press 2011-05-01
• Series: OncoTargets and Therapy
• Online Access: http://www.dovepress.com/an-update-on-trovaxreg-for-the-treatment-of-progressive-castration-res-a7523
• ISSN: 1178-6930

Michael Abern1, Howard L Kaufman2, Kalyan Latchamsetty11Department of Urology, Rush University Medical Center, Chicago, IL, USA; 2Department of General Surgery and Immunology and Microbiology, Rush University Medical Center, Chicago, IL, USAAbstract: Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax®) vaccine.Keywords: castration resistance, prostate cancer, TroVax, vaccine